In April 2026, CITEST Diagnostics Inc. launched the CTA-VFC Fluorescence Immunoassay Analyzer, a cutting-edge point-of-care solution built for veterinary diagnostics worldwide. Engineered with advanced antigen-antibody interaction technology, the instrument detects fluorescence signals from immunoassays to deliver accurate quantitative or qualitative analysis of animal samples via dedicated test modules, combining high accuracy, excellent stability, and rapid results for reliable, efficient veterinary clinical use.

Designed for modern veterinary practices, the CTA-VFC stands out with user-centric advantages: it stores up to 10,000 result records for seamless patient history tracking, delivers read times under 20 seconds to cut wait times, and features a built-in thermal printer for instant test report generation. Its compact, lightweight design makes it ideal for small clinics, mobile units, and field testing, while LIS compatibility ensures smooth integration with existing practice management systems.

Built for consistent high performance, the analyzer operates on fluorescence immunoassay principles, supporting cassette-format testing for both quantitative and qualitative measurements. It includes a 7-inch display, 1 LAN, 2 USB, and 1 COM ports for full connectivity, housed in a 244.5mm×240mm×201.4mm footprint with a 2.2kg net weight for maximum portability. Sample type specifications are detailed in individual test package inserts, ensuring flexibility across diverse veterinary diagnostic needs.

The CTA-VFC fills a critical gap in veterinary point-of-care diagnostics, delivering lab-grade accuracy without complex infrastructure, making precision testing accessible to practices of all sizes. By merging speed, portability, and workflow efficiency, the CTA-VFC solidifies CITEST’s position as a trusted leader in veterinary diagnostic innovation, prioritizing animal health and practice excellence.